IMAB Key Statistics, Chart & Performance
The current stock price of IMAB is 4.63 USD. In the past month the price increased by 19.95%. In the past year, price increased by 332.71%.
IMAB Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IMAB. When comparing the yearly performance of all stocks, IMAB is one of the better performing stocks in the market, outperforming 98.79% of all stocks.
IMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMAB. While IMAB has a great health rating, there are worries on its profitability.
IMAB Financial Highlights
Over the last trailing twelve months IMAB reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 89.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.22% | ||
| ROE | -19.14% | ||
| Debt/Equity | 0 |
IMAB Forecast & Estimates
12 analysts have analysed IMAB and the average price target is 8.5 USD. This implies a price increase of 83.58% is expected in the next year compared to the current price of 4.63.
IMAB Ownership
IMAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.08 | 385.48B | ||
| AMGN | AMGEN INC | 15.19 | 178.88B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.51 | 112.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 78.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 711.09 | 47.91B | ||
| INSM | INSMED INC | N/A | 34.69B | ||
| NTRA | NATERA INC | N/A | 33.19B | ||
| BIIB | BIOGEN INC | 10.1 | 24.80B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.89B | ||
| INCY | INCYTE CORP | 16.36 | 20.62B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.93 | 20.37B |
Related stock screener links
About IMAB
Company Profile
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Company Info
I-MAB-SPONSORED ADR
Suite 400, 2440 Research Blvd
Rockville MARYLAND 201210 US
CEO: Joan Huaqiong Shen
Employees: 32
Phone: 13016702800
I-MAB-SPONSORED ADR / IMAB FAQ
What does IMAB do?
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
What is the stock price of I-MAB-SPONSORED ADR today?
The current stock price of IMAB is 4.63 USD. The price decreased by -0.22% in the last trading session.
What is the dividend status of I-MAB-SPONSORED ADR?
IMAB does not pay a dividend.
What is the ChartMill rating of I-MAB-SPONSORED ADR stock?
IMAB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does I-MAB-SPONSORED ADR have?
I-MAB-SPONSORED ADR (IMAB) currently has 32 employees.
Can you provide the market cap for I-MAB-SPONSORED ADR?
I-MAB-SPONSORED ADR (IMAB) has a market capitalization of 533.68M USD. This makes IMAB a Small Cap stock.